Dare Bioscience Inc (DARE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $12.93M
Last updated: Nov 17, 2026 at 11:03 AM ET
Dare Bioscience Inc (DARE) Stock Forecast
Analysts expect Dare Bioscience (DARE) to earn -$0.73 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.75M. Of 3 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 1.67, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 33.3% |
| Buy | 2 | 66.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 169.1%.
- Fiscal year ending Dec 31, 2026
- -$0.73
- EPS consensus, revenue $2.75M
- Fiscal year ending Dec 31, 2027
- -$0.51
- EPS consensus, revenue $7.40M
- Next report
- Mar 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.73 | -$0.92 to -$0.43 | 3 | $2.75M | $340000 to $7.14M | 3 |
| Dec 31, 2027 | -$0.51 | -$0.71 to -$0.31 | 2 | $7.40M | $2.43M to $12.37M | 2 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.24 | -$0.29 to -$0.17 | 5 | $366517 | N/A | 5 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.95.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.73 | -$0.77 | -$0.77 | -$0.77 | -$0.95 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.51 | -$0.42 | -$0.42 | -$0.42 | -$0.51 | N/A |
Frequently Asked Questions About DARE
What is the DARE stock forecast?
Consensus analyst estimates put Dare Bioscience's EPS at -$0.73 for the fiscal year ending Dec 31, 2026, on revenue of $2.75M. The consensus rating from 3 analysts is Buy.
How do analysts rate DARE stock?
Of 3 analysts covering Dare Bioscience, 1 rates it Strong Buy, 2 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from DARE next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.73, with estimates from -$0.92 to -$0.43 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.51, with estimates from -$0.71 to -$0.31 from 2 analysts.
What revenue do analysts expect from Dare Bioscience next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.75M, with estimates from $340000 to $7.14M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $7.40M, with estimates from $2.43M to $12.37M.
How many analysts cover DARE?
3 analysts rate Dare Bioscience stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
DARE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors